<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="67040">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01788839</url>
  </required_header>
  <id_info>
    <org_study_id>12-249</org_study_id>
    <nct_id>NCT01788839</nct_id>
  </id_info>
  <brief_title>Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma</brief_title>
  <official_title>Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan-Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan-Kettering Cancer Center</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see how cancer treatment affects sexual and reproductive
      function.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>determine the natural history of sexual and reproductive health</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>predictors of sexual dysfunction during and after treatment</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>impact of treatment on self-reported future pregnancy/reproductive health</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>factors that influence decisions regarding fertility preservation</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Before treatment and family building after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparison of sexual function between breast cancer and lymphoma patients</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Lymphoma</condition>
  <condition>Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>women with breast cancer</arm_group_label>
    <description>This study is a prospective, observational, longitudinal study assessing the prevalence of sexual dysfunction and distress in premenopausal women with breast cancer. This study will also evaluate the severity, time course, and predictors of sexual dysfunction. Breast cancer patients and survivors will be administered surveys of comprehensive questionnaires related to sexual function.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>women with lymphoma</arm_group_label>
    <description>This study is a prospective, observational, longitudinal study assessing the prevalence of sexual dysfunction and distress in premenopausal women with   Diffuse Large B-cell Lymphoma or Hodgkin's Lymphoma. This study will also evaluate the severity, time course, and predictors of sexual dysfunction. Lymphoma patients and survivors will be administered surveys of comprehensive questionnaires related to sexual function.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>surveys</intervention_name>
    <description>A survey including the Female Sexual Function Index (FSFI), the Modified Female Sexual Function Index (FSFI-M), the Sexual Activity Questionnaire (SAQ), the Female Sexual Distress Scale (FSDS-R), the Menopausal Symptom Check List (MSCL), Patient-reported Outcomes Measurement Information System Sexual Function Instrument (PROMIS-SF), Abbreviated Dyadic Adjustment Scale for Relationships (ADAS), Reproductive Health Survey-baseline (RHS-B). Reproductive Health Survey-followup and (RHS-F1)Reproductive Health Survey-followup (RHS-F2) will be conducted at the following intervals: baseline/before chemotherapy +/- 1 month, 3 months after baseline +/- 1 month, 6 months after baseline +/- 1 month, 1 year after baseline +/- 1 month, and at intervals during survivorship that include yearly for 5 years +/- 1 month.</description>
    <arm_group_label>women with breast cancer</arm_group_label>
    <arm_group_label>women with lymphoma</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women ages 18 to 50, who are premenopausal with a new diagnosis of stage 0-III breast
        cancer or Diffuse Large B-cell Lymphoma or Hodgkin's Lymphoma will be recruited from
        breast cancer and lymphoma clinics.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Premenopausal women at time of diagnosis ages 18 to 50 who have either been pregnant
             or had at least one menstrual period in the last 12 months

          -  Women with newly diagnosed breast cancer (stage 0-III) or Diffuse Large B-cell
             Lymphoma or Hodgkin's Lymphoma within 1 month of starting systemic treatment

          -  Breast cancer patients with any receptor type

          -  English speaking

          -  Able to participate in the informed consent process

        Exclusion Criteria:

          -  Active secondary cancer requiring cytotoxic chemotherapy

          -  Prior systemic treatment for a malignancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shari Goldfarb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan-Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shari Goldfarb, MD</last_name>
    <phone>646-888-5080</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maura Dickler, MD</last_name>
    <phone>646-888-5456</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering at Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shari Goldfarb, MD</last_name>
      <phone>646-888-5080</phone>
    </contact>
    <contact_backup>
      <last_name>Maura Dickler, MD</last_name>
      <phone>646-888-5456</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center @ Suffolk</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shari Goldfarb, MD</last_name>
      <phone>646-888-5080</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shari Goldfarb, MD</last_name>
      <phone>646-888-5080</phone>
    </contact>
    <contact_backup>
      <last_name>Maura Dickler, MD</last_name>
      <phone>646-888-5456</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering at Mercy Medical Center</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shari Goldfarb, MD</last_name>
      <phone>646-888-5080</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center</name>
      <address>
        <city>Sleepy Hollow</city>
        <state>New York</state>
        <zip>10591</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shari Goldfarb, MD</last_name>
      <phone>646-888-5080</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/</url>
    <description>Memorial Sloan-Kettering Cancer Center</description>
  </link>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 2, 2014</lastchanged_date>
  <firstreceived_date>February 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sexual and Reproductive Health</keyword>
  <keyword>premenopausal</keyword>
  <keyword>Fertility</keyword>
  <keyword>12-249</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
